Study on the effectiveness and safety of low-dose cyclophosphamide combined with TKI, PD-1 and TACE in the treatment of unresectable HCC

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053364

Enrollment

Unknown

Registered

2021-11-20

Start date

2021-11-30

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Experimental group:CTX

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with unresectable liver cancer diagnosed by pathology and/or clinically.

Exclusion criteria

Exclusion criteria: 1.Those who are allergic to the study drug; 2.Those who have related drug contraindications, and those who have received other treatments in the past.

Design outcomes

Primary

Measure	Time frame
Objective response rate;	—

Countries

China

Contacts

Public ContactDeng Meihai

The Third Affiliated Hospital of Sun Yat-Sen University

dengmeih@mail.sysu.edu.cn+86 13318818899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026